Biosimilars

Nominations for the 2017 Power List are now open and will close on February 1, 2017.

After finally breaking into the US market, biosimilars have created a real buzz in the industry, but the best practice for demonstrating similarity can be daunting to say the least.

Taylor Dispersion Analysis is an ultra-low volume, microcapillary flow technique for sizing and stability of biomolecules in complex solutions, and offers advantages for orthogonal and complementary biophysical characterization measurements.

In-depth analysis of original and new candidate drugs for biosimilars is easier than ever before…

Sitting Down With… Carsten Brockmeyer, CEO, Formycon, Germany.

The first US biosimilar - Zarxio from Sandoz - has been cleared for market. But the judges say it wasn't an easy decision.

Taylor Dispersion measurements are used to monitor self-association and oligomeric state in a variety of buffer conditions.

The rise of biosimilars is great news for overburdened healthcare systems, but it’s a very different proposition to a simple generic.

In the midst of wrangles over biosimilars naming and interchangeability, let’s not forget the key benefit...

A US government study reports progress – but also highlights shortfalls